secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-032043
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience Q3 revenue ex-license $235K, up 484% YoY; cash $0.3M, closes $0.35M debt
--------------------------------------------------------------------------------

- Revenue (ex-license) $235,321 (+484% YoY, +61% sequential); clinic revenue $176,395 (+370%), product sales $58,926 (+2,012%).
- Combined clinic revenue (consolidated + equity) $450,131 (+1,100% YoY, +111% sequential).
- Cash $0.3M at Sept 30; raised $0.35M in interim demand notes post-quarter; seeking additional funding.
- Adjusted EBITDA -$2.0M vs -$1.6M; gross margin 54% vs 49% adjusted prior year; no GAAP net income disclosed.
- Completed due diligence on clinic acquisition; Tampa INVO Center expected Q1 2023; updated 510(k) filed for 5-day incubation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315222032043/0001493152-22-032043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315222032043/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer